Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma

Molecular Carcinogenesis

Volumn 46, Issue 11, 2007, Pages 901-911

  Jin, Xin ^a,b   Song, Xin ^a   Li, Lili ^a   Wang, Zhenlian ^a   Tao, Yongguang ^a   Deng, Lin ^a   Tang, Ming ^a   Yi, Wei ^a   Cao, Ya ^a  

^a Central South University   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

c jun; Cell cycle; Epstein Barr virus; Heterodimer; Jun B; Latent membrane protein 1; Nasopharyngeal carcinoma; TAM67

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; LATENT MEMBRANE PROTEIN 1; MESSENGER RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASES; HUMANS; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 35848944885     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20319     Document Type: Article

References (52)

1. Rickinson AB. Epstein-Barr virus in action in vivo. N Engl J Med 1998;338:1461-1463.
2. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-2697.
3. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-338.
4. Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-1065.
5. Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 1984;81:7207-7211.
6. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa Band cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-560.
7. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997;94:1447-1452.
8. Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000;19:2657-2663.
9. Maslyar DJ, Aoki M, Vogt PK. The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. Oncogene 2001;20:5087-5092.
10. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999;18:188-197.
11. Smith LM, Wise SC, Hendricks DT, et al. c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999;18:6063-6070.
12. Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J 1997;16:1695-1709.
13. Wang N, Verna L, Hardy S, et al. c-Jun triggers apoptosis in human vascular endothelial cells. Circ Res 1999;85:387-393.
14. Passegue E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 2000;19:2969-2979.
15. Jacobs-Helber SM, Abutin RM, Tian C, Bondurant M, Wickrema A, Sawyer ST. Role of JunB in erythroid differentiation. J Biol Chem 2002;277:4859-4866.
16. Chalaux E, Lopez-Rovira T, Rosa JL, Bartrons R, Ventura F. JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. J Biol Chem 1998;273:537-543.
17. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003;101:1513-1519.
18. Robinson CM, Prime SS, Huntley S, et al. Overexpression of JunB in undifferentiated malignant rat oral keratinocytes enhances the malignant phenotype in vitro without altering cellular differentiation. Int J Cancer 2001;91:625-630.
19. Schlingensiepen KH, Schlingensiepen R, Kunst M, et al. Opposite functions of jun-B and c-jun in growth regulation and neuronal differentiation. Dev Genet 1993;14:305-312.
20. Wang C, Deng X, Li X, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus LMP1 via NF-kappa B or AP-1 signaling pathway in nasopharyngeal carcinoma cells. Zhonghua Zhong Liu Za Zhi 2002;24:9-13.
21. Song X, Tao YG, Deng XY, et al. Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein-Barr virus encoded latent membrane protein 1. Cell Signal 2004;16:1153-1162.
22. Deng L, Yang J, Zhao XR, et al. Cells in G2/M phase increased in human nasopharyngeal carcinoma cell line by EBV-LMP1 through activation of NF-kappaB and AP-1. Cell Res 2003;3:187-194.
23. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999;19:2690-2698.
24. Rotheneder H, Geymayer S, Haidweger E. Transcription factors of the Sp 1 family: Interaction with E2F and regulation of the murine thymidine kinase promoter. J Mol Biol 1999;293:1005-1015.
25. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-3355.
26. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994;91:609-613.
27. Dong Z, Crawford HC, Lavrovsky V, et al. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 1997;19:204-212.
28. Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res 2003;1:848-854.
29. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996;271:8313-8320.
30. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997;17:5771-5783.
31. Kaelin WG Jr. Functions of the retinoblastoma protein. Bioessays 1999;21:950-958.
32. Zhao XR, Gu HH, Weng XX, Yi W, Deng XY, Cao Y. The primary study on expression and function of D-type cyclins in nasopharyngeal carcinoma cell lines. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2000;32:192-196.
33. Hu LF, Chen F, Zheng X, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8:1575-1583.
34. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 2004;23:8238-8246.
35. Suto R, Tominaga K, Mizuguchi H, et al. Dominant-negative mutant of c-Jun gene transfer: A novel therapeutic strategy for colorectal cancer. Gene Ther 2004;11:187-193.
36. Liu Y, Ludes-Meyers J, Zhang Y, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-7689.
37. Kondo S, Wakisaka N, Schell MJ, et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: Enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer 2005;115:368-376.
38. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000;60:2555-2561.
39. Kielosto M, Nummela P, Katainen R, Leaner V, Birrer MJ, Holtta E. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun. Cancer Res 2004;64:3772-3779.
40. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of c-Jun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ 1996;7:1013-1021.
41. Thompson EJ, Gupta A, Stratton MS, Bowden GT. Mechanism of action of a dominant negative c-jun mutant in inhibiting activator protein-1 activation. Mol Carcinog 2002;35:157-162.
42. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001;21:4773-4784.
43. Glassford J, Holman M, Banerji L, et al. Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen Receptor. J Biol Chem 2001;27:41040-41048.
44. Parada Y, Banerji L, Glassford J, et al. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem 2001;276:23572-23580.
45. Bremner R, Cohen BL, Sopta M, et al. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995;15:256-265.
46. Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. Mol Biol Cell 2001;12:2352-2363.
47. Herber B, Truss M, Beato M. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Oncogene 1994;9:2105-2107.
48. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:69-674.
49. Blum JH, Dove SL, Hochschild A, Mekalanos JJ. Isolation of peptide aptamers that inhibit intracellular processes. Proc Natl Acad Sci USA 2000;97:2241-2246.
50. Cooper S, Ranger-Moore J, Bowden TG. Differential inhibition of UVB-induced AP-1 and NF-kappaB transactivation by components of the jun bZIP domain. Mol Carcinog 2005;43:108-116.
51. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-2721.
52. Yin L, Liao W, Yi W, et al. LMP1 activates NF-kappa B via degradation of I kappa B alpha in nasopharyngeal carcinoma cells. Chin Med J (Engl) 2001;114:718-722.